Wikipedia
Ever since Medicare was given power to negotiate prices for certain medicines, the pharmaceutical industry has argued the move will end badly for patients.
Beyond complaining about price controls and unconstitutional mandates, the key message aimed at the American public has been that innovation will suffer.
advertisement
This is a familiar but tiring refrain.
Get unlimited access to award-winning journalism and exclusive events.
Subscribe Log In
Previous article：
The cancer drug shortage isn’t new — and neither are the solutions
Next article： Medicare details structure of new drug price negotiation program
Next article： Medicare details structure of new drug price negotiation program
